Biosimilars have tremendous potential to reduce the high cost of biologics and increase the affordability of biologics medicines. For innovation companies, highly differentiated and technologically advanced biobetters offer the greatest potential to mitigate the risks associated with the introduction of biosimilars, as they can be approved before the patent expires and have blockbuster potential.
Download the technical paper now to learn more about the challenges and opportunities of the next generation! |
|
|
|
